Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | GMPS | P49915 | 1/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311195 | 0.85 | EGFR (0.44) | DOT1L | |
| SCHEMBL21311194 | 0.78 | PI4KA (0.48) | ADORA3ADORA2AGMPSSLC28A1 | |
| SCHEMBL20097120 | 0.77 | DOT1L (0.63) | DOT1LADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL21311216 | 0.76 | ADORA2A (0.47) | DOT1LADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL25521510 | 0.76 | ADORA3 (0.53) | DOT1LADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL23025515 | 0.76 | ADORA3 (0.53) | DOT1LADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL21311193 | 0.76 | DOT1L (0.38) | DOT1LADORA3ADORA2AGMPSSLC28A1 | |
| SCHEMBL22837929 | 0.75 | TRPM2 (0.46) | — | |
| SCHEMBL21311217 | 0.75 | ADORA2A (0.47) | DOT1LADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL21311154 | 0.75 | ADORA3 (0.47) | DOT1LADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | DOT1L 2274/4885MCHR1 4529/4885ADORA3 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.